Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
Affiliations
- PMID: 9305507
Item in Clipboard
Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
Alzheimer Dis Assoc Disord.
1997.
No abstract available
Similar articles
-
Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:61-4. Alzheimer Dis Assoc Disord. 1997. PMID: 9305520 No abstract available.
-
Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:34-8. Alzheimer Dis Assoc Disord. 1997. PMID: 9305514 No abstract available.
-
Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:22-5. Alzheimer Dis Assoc Disord. 1997. PMID: 9305510
-
Outcomes for clinical trials in mild-to-moderate dementia to evaluate drugs with presumably symptomatic effects.J Nutr Health Aging. 2007 Jul-Aug;11(4):357-8. J Nutr Health Aging. 2007. PMID: 17653499 Review. No abstract available.
-
Neuropsychiatric outcome for clinical trials.J Nutr Health Aging. 2007 Jul-Aug;11(4):345-7. J Nutr Health Aging. 2007. PMID: 17653496 Review. No abstract available.
Cited by
-
Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease.Alzheimers Res Ther. 2018 Jun 29;10(1):61. doi: 10.1186/s13195-018-0386-7. Alzheimers Res Ther. 2018. PMID: 29958538 Free PMC article.
-
Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.Drugs Aging. 2004;21(9):607-20. doi: 10.2165/00002512-200421090-00005. Drugs Aging. 2004. PMID: 15260515
-
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.Alzheimers Res Ther. 2015 Mar 8;7(1):9. doi: 10.1186/s13195-014-0088-8. eCollection 2015. Alzheimers Res Ther. 2015. PMID: 25755685 Free PMC article.
-
Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.CNS Drugs. 2004;18(13):853-75. doi: 10.2165/00023210-200418130-00003. CNS Drugs. 2004. PMID: 15521790 Review.
-
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):583-91. doi: 10.1177/1533317513495104. Am J Alzheimers Dis Other Demen. 2013. PMID: 23982674 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Medical